113 related articles for article (PubMed ID: 26498857)
1. Protein-protein interactions of PDE4 family members - Functions, interactions and therapeutic value.
Klussmann E
Cell Signal; 2016 Jul; 28(7):713-8. PubMed ID: 26498857
[TBL] [Abstract][Full Text] [Related]
2. Uncovering the function of Disrupted in Schizophrenia 1 through interactions with the cAMP phosphodiesterase PDE4: Contributions of the Houslay lab to molecular psychiatry.
Brandon NJ
Cell Signal; 2016 Jul; 28(7):749-52. PubMed ID: 26432168
[TBL] [Abstract][Full Text] [Related]
3. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.
Houslay MD; Adams DR
Biochem J; 2003 Feb; 370(Pt 1):1-18. PubMed ID: 12444918
[TBL] [Abstract][Full Text] [Related]
4. Ndel1 alters its conformation by sequestering cAMP-specific phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA).
Collins DM; Murdoch H; Dunlop AJ; Charych E; Baillie GS; Wang Q; Herberg FW; Brandon N; Prinz A; Houslay MD
Cell Signal; 2008 Dec; 20(12):2356-69. PubMed ID: 18845247
[TBL] [Abstract][Full Text] [Related]
5. Identification of a multifunctional docking site on the catalytic unit of phosphodiesterase-4 (PDE4) that is utilised by multiple interaction partners.
Houslay KF; Christian F; MacLeod R; Adams DR; Houslay MD; Baillie GS
Biochem J; 2017 Feb; 474(4):597-609. PubMed ID: 27993970
[TBL] [Abstract][Full Text] [Related]
6. PDE4 associates with different scaffolding proteins: modulating interactions as treatment for certain diseases.
McCahill AC; Huston E; Li X; Houslay MD
Handb Exp Pharmacol; 2008; (186):125-66. PubMed ID: 18491051
[TBL] [Abstract][Full Text] [Related]
7. UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy.
Wang L; Burmeister BT; Johnson KR; Baillie GS; Karginov AV; Skidgel RA; O'Bryan JP; Carnegie GK
Cell Signal; 2015 May; 27(5):908-22. PubMed ID: 25683917
[TBL] [Abstract][Full Text] [Related]
8. Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains.
Bolger GB; Dunlop AJ; Meng D; Day JP; Klussmann E; Baillie GS; Adams DR; Houslay MD
Cell Signal; 2015 Apr; 27(4):756-69. PubMed ID: 25546709
[TBL] [Abstract][Full Text] [Related]
9. cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling.
Houslay MD; Baillie GS; Maurice DH
Circ Res; 2007 Apr; 100(7):950-66. PubMed ID: 17431197
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.
Pullamsetti SS; Banat GA; Schmall A; Szibor M; Pomagruk D; Hänze J; Kolosionek E; Wilhelm J; Braun T; Grimminger F; Seeger W; Schermuly RT; Savai R
Oncogene; 2013 Feb; 32(9):1121-34. PubMed ID: 22525277
[TBL] [Abstract][Full Text] [Related]
11. Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK.
Li X; Vadrevu S; Dunlop A; Day J; Advant N; Troeger J; Klussmann E; Jaffrey E; Hay RT; Adams DR; Houslay MD; Baillie GS
Biochem J; 2010 Apr; 428(1):55-65. PubMed ID: 20196770
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase type 4 anchoring regulates cAMP signaling to Popeye domain-containing proteins.
Tibbo AJ; Mika D; Dobi S; Ling J; McFall A; Tejeda GS; Blair C; MacLeod R; MacQuaide N; Gök C; Fuller W; Smith BO; Smith GL; Vandecasteele G; Brand T; Baillie GS
J Mol Cell Cardiol; 2022 Apr; 165():86-102. PubMed ID: 34999055
[TBL] [Abstract][Full Text] [Related]
13. PDE4D phosphorylation: A coincidence detector integrating multiple signaling pathways.
Mika D; Conti M
Cell Signal; 2016 Jul; 28(7):719-24. PubMed ID: 26562185
[TBL] [Abstract][Full Text] [Related]
14. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown.
Houslay MD
Trends Biochem Sci; 2010 Feb; 35(2):91-100. PubMed ID: 19864144
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase 4D: an enzyme to remember.
Ricciarelli R; Fedele E
Br J Pharmacol; 2015 Oct; 172(20):4785-9. PubMed ID: 26211680
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
17. Arrestin-dependent localization of phosphodiesterases.
Willis MJ; Baillie GS
Handb Exp Pharmacol; 2014; 219():293-307. PubMed ID: 24292836
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders.
Wu C; Rajagopalan S
Obes Rev; 2016 May; 17(5):429-41. PubMed ID: 26997580
[TBL] [Abstract][Full Text] [Related]
19. Understanding PDE4's function in Alzheimer's disease; a target for novel therapeutic approaches.
Tibbo AJ; Tejeda GS; Baillie GS
Biochem Soc Trans; 2019 Oct; 47(5):1557-1565. PubMed ID: 31642904
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase-4 Inhibition in Parkinson's Disease: Molecular Insights and Therapeutic Potential.
Roy D; Balasubramanian S; Krishnamurthy PT; Sola P; Rymbai E
Cell Mol Neurobiol; 2023 Aug; 43(6):2713-2741. PubMed ID: 37074485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
